Compare Stocks: TLSA, DBVT, STTK, and VECT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.80 +2.6%	$12.87	$9.36 ▼ $26.18	$616.20M	-1.04	474,307 shs	324,040 shs
STTK Shattuck Labs	$5.97 +5.5%	$6.80	$1.70 ▼ $8.33	$599.17M	1.09	1.66 million shs	1.05 million shs
TLSA Tiziana Life Sciences	$1.19 +5.3%	$1.02	$0.76 ▼ $2.25	$151.44M	0.45	682,694 shs	2.42 million shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	-7.11%	-24.44%	-40.57%	-38.29%
STTK Shattuck Labs	0.00%	-11.29%	-2.93%	-10.09%	+149.79%
TLSA Tiziana Life Sciences	0.00%	+6.25%	+23.44%	-3.25%	-48.03%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.80 +2.6%	$12.87	$9.36 ▼ $26.18	$616.20M	-1.04	474,307 shs	324,040 shs
STTK Shattuck Labs	$5.97 +5.5%	$6.80	$1.70 ▼ $8.33	$599.17M	1.09	1.66 million shs	1.05 million shs
TLSA Tiziana Life Sciences	$1.19 +5.3%	$1.02	$0.76 ▼ $2.25	$151.44M	0.45	682,694 shs	2.42 million shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	-7.11%	-24.44%	-40.57%	-38.29%
STTK Shattuck Labs	0.00%	-11.29%	-2.93%	-10.09%	+149.79%
TLSA Tiziana Life Sciences	0.00%	+6.25%	+23.44%	-3.25%	-48.03%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.67	Moderate Buy	$48.50	394.90% Upside
STTK Shattuck Labs	3.00	Buy	$13.33	123.34% Upside
TLSA Tiziana Life Sciences	2.00	Hold	N/A	N/A
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TLSA, DBVT, STTK, and VECT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	STTK Shattuck Labs	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$11.00 ➝ $14.00
10/2/2026	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $19.00
9/30/2026	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/22/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/11/2026	STTK Shattuck Labs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/3/2026	TLSA Tiziana Life Sciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/26/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Strong-Buy	$18.00
8/24/2026	STTK Shattuck Labs	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$5.64M	109.26	N/A	N/A	$4.20 per share	2.33
STTK Shattuck Labs	$1M	599.15	N/A	N/A	$1.30 per share	4.59
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
STTK Shattuck Labs	-$48.81M	-$0.51	N/A	N/A	N/A	N/A	-43.57%	-40.90%	11/10/2026 (Estimated)
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TLSA, DBVT, STTK, and VECT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
10/28/2026	Q3 2026	DBVT DBV Technologies	-$0.1617	N/A	N/A	N/A	$0.66 million	N/A
8/11/2026	Q2 2026	STTK Shattuck Labs	-$0.1241	-$0.12	+$0.0041	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	3.72	3.72
STTK Shattuck Labs	N/A	27.59	27.59
TLSA Tiziana Life Sciences	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
STTK Shattuck Labs	58.74%
TLSA Tiziana Life Sciences	N/A
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.06%
STTK Shattuck Labs	8.79%
TLSA Tiziana Life Sciences	39.82%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
STTK Shattuck Labs	40	100.36 million	91.54 million	Optionable
TLSA Tiziana Life Sciences	10	127.26 million	76.58 million	Optionable
VECT VectivBio	30	N/A	N/A	No Data

TLSA, DBVT, STTK, and VECT Headlines

Recent News About These Companies

Ironwood Pharma to acquire VectivBio for $1.15 bln

July 12, 2026 | nasdaq.com

VectivBio Announces Pricing of Initial Public Offering

June 16, 2026 | stockhouse.com

What Recent Medicare Pricing Terms Mean For The Ironwood Pharmaceuticals (IRWD) Investment Story

February 6, 2026 | finance.yahoo.com

Boston biotech settles lawsuit alleging misappropriation of GLP-2 analog intellectual property

December 23, 2025 | bizjournals.com

Biotech acquired by Ironwood faces allegations of misappropriating trade secrets

November 11, 2025 | bizjournals.com

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.comB

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.comG

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.comM

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

IFLR Europe Awards 2024: shortlist revealed

February 8, 2024 | iflr.comI

Ironwood seals the deal on VectivBio merger

December 13, 2023 | msn.com

Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio

December 12, 2023 | finance.yahoo.com

Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines

November 15, 2023 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, DBVT, STTK, and VECT Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.80 +0.25 (+2.62%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.80 +0.00 (+0.05%)

As of 10/9/2026 06:43 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Shattuck Labs NASDAQ:STTK

$5.97 +0.31 (+5.48%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.96 -0.01 (-0.18%)

As of 10/9/2026 07:30 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Tiziana Life Sciences NASDAQ:TLSA

$1.19 +0.06 (+5.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.18 -0.01 (-0.92%)

As of 10/9/2026 07:30 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 10/9/2026

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, DBVT, STTK, and VECT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, DBVT, STTK, and VECT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, DBVT, STTK, and VECT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, DBVT, STTK, and VECT Company Descriptions

DBV Technologies NASDAQ:DBVT

Shattuck Labs NASDAQ:STTK

Tiziana Life Sciences NASDAQ:TLSA

VectivBio NASDAQ:VECT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TLSA, DBVT, STTK, and VECT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TLSA, DBVT, STTK, and VECT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TLSA, DBVT, STTK, and VECT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA, DBVT, STTK, and VECT Company Descriptions

DBV Technologies NASDAQ:DBVT

Shattuck Labs NASDAQ:STTK

Tiziana Life Sciences NASDAQ:TLSA

VectivBio NASDAQ:VECT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools